# LBRX (LB Pharmaceuticals Inc) - SEC EDGAR Financial Statements

> LB Pharmaceuticals Inc reported $453.4M in total assets and a net loss of $141.2M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/LBRX
- Markdown: https://convexityos.com/fundamentals/LBRX.md
- SEC CIK: 0001691082
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:26 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001691082&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$152.4M | Operating profit |
| Net Income | FY 2025 | -$141.2M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$4.27 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$143.8M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $403.8M | Total debt: $5.16M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Research & Development | $16.74M | $51.17M |
| Total Operating Expenses | $30.40M | $64.83M |
| **Operating Income** | -$30.40M | -$64.83M |
| **EBITDA** | -$30.08M | -$64.74M |
| Interest Income | $3.92M | $1.72M |
| Income Before Tax | -$25.20M | -$63.10M |
| Income Tax Expense | $1.0K | $1.0K |
| **Net Income** | -$25.20M | -$63.10M |
| Basic EPS | -$3.13 | -$176.15 |
| **Diluted EPS** | -$3.13 | -$176.15 |
| Basic Shares Outstanding | 8.0M | 358.2K |
| Diluted Shares Outstanding | 8.0M | 358.2K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $51.52M | $44.15M | $14.64M | $8.48M | $2.42M | $2.42M | $3.42M | -- |
| Total Operating Expenses | $62.50M | $53.91M | $22.10M | $13.87M | $5.25M | $4.86M | $6.43M | -- |
| **Operating Income** | -$62.50M | -$53.91M | -$22.10M | -$13.87M | -$5.25M | -$4.86M | -$6.43M | -- |
| **EBITDA** | -$62.37M | -$53.82M | -$22.02M | -- | -$5.17M | -$4.78M | -$6.35M | -- |
| Interest Income | $3.77M | $2.97M | $2.85M | $2.80M | $707K | $177K | $236K | -- |
| Income Before Tax | -$59.07M | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -- |
| Income Tax Expense | $0 | $0 | $0 | $1.0K | $0 | $0 | $0 | -- |
| **Net Income** | -$59.07M | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -$5.07M |
| Basic EPS | -$1.79 | -$1.71 | -$0.67 | -- | -$0.61 | -$13.58 | -$14.79 | -- |
| **Diluted EPS** | -$1.79 | -$1.71 | -$0.67 | -- | -$0.61 | -$13.58 | -$14.79 | -- |
| Basic Shares Outstanding | 33.1M | 30.1M | 28.2M | -- | 5.8M | 358.8K | 358.8K | -- |
| Diluted Shares Outstanding | 33.1M | 30.1M | 28.2M | -- | 5.8M | 358.8K | 358.8K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Cash & Cash Equivalents | $250.2M | $22.98M |
| Short-Term Investments | $45.04M | $5.02M |
| **Cash & Short-Term Investments** | $295.2M | $25.45M |
| **Total Current Assets** | $308.4M | $28.88M |
| Property, Plant & Equipment, Net | $1.58M | $1.86M |
| **Total Non-Current Assets** | $4.50M | $4.66M |
| **Total Assets** | $312.9M | $33.53M |
| Accounts Payable | $2.13M | $2.32M |
| **Total Current Liabilities** | $7.44M | $8.11M |
| **Total Non-Current Liabilities** | $4.18M | $5.72M |
| **Total Liabilities** | $11.62M | $13.83M |
| **Total Debt (incl. Leases)** | $3.57M | $3.70M |
| Common Stock | $3.0K | $1.0K |
| Retained Earnings | -$129.5M | -$104.3M |
| Accumulated Other Comp. Income | $168K | $111K |
| **Total Stockholders' Equity** | $301.3M | -$94.55M |
| Total Equity | $301.3M | -$94.55M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $215.1M | $283.1M | $320.7M | $250.2M | $269.7M | $22.98M |
| Short-Term Investments | $188.7M | $44.68M | $44.96M | $45.04M | $44.73M | $5.02M |
| **Cash & Short-Term Investments** | $403.2M | $324.9M | $364.9M | $295.2M | $314.5M | $25.45M |
| **Total Current Assets** | $447.1M | $355.3M | $389.1M | $308.4M | $316.4M | $28.88M |
| Property, Plant & Equipment, Net | $2.15M | $2.20M | $1.53M | $1.58M | $1.64M | $1.86M |
| **Total Non-Current Assets** | $6.25M | $6.39M | $4.41M | $4.50M | $4.34M | $4.66M |
| **Total Assets** | $453.4M | $361.7M | $393.5M | $312.9M | $320.7M | $33.53M |
| Accounts Payable | $6.88M | $3.49M | $7.12M | $2.13M | $2.59M | $2.32M |
| **Total Current Liabilities** | $30.25M | $23.56M | $10.91M | $7.44M | $6.65M | $8.11M |
| **Total Non-Current Liabilities** | $5.48M | $5.78M | $3.88M | $4.18M | $3.88M | $5.72M |
| **Total Liabilities** | $35.73M | $29.34M | $14.79M | $11.62M | $10.53M | $13.83M |
| **Total Debt (incl. Leases)** | $5.16M | $5.22M | $3.47M | $3.57M | $3.67M | $3.70M |
| Common Stock | $3.0K | $3.0K | $3.0K | $3.0K | $114.3M | $1.0K |
| Retained Earnings | -$259.3M | -$200.2M | -$148.6M | -$129.5M | -$118.1M | -$104.3M |
| Accumulated Other Comp. Income | -$545K | $186K | $208K | $168K | -$53K | $111K |
| **Total Stockholders' Equity** | $417.6M | $332.3M | $378.7M | $301.3M | $310.2M | -$94.55M |
| Total Equity | $417.6M | $332.3M | $378.7M | $301.3M | $310.2M | -$94.55M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Net Income | -$25.20M | -$63.10M |
| Depreciation & Amortization | $321K | $91K |
| Stock-Based Compensation | $4.19M | $3.09M |
| **Operating Cash Flow** | -$35.21M | -$53.05M |
| Capital Expenditure | -$52K | -$769K |
| **Free Cash Flow** | -$35.26M | -$53.82M |
| Purchases of Investments | -$44.84M | -$29.75M |
| Sales & Maturities of Investments | $5.00M | $53.75M |
| **Investing Cash Flow** | -$39.89M | $23.23M |
| **Financing Cash Flow** | $302.6M | $38.31M |
| **Net Change in Cash** | $227.5M | $8.50M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$59.07M | -$51.60M | -$19.05M | -$11.47M | -$3.56M | -$4.87M | -$5.31M | -$5.07M |
| Depreciation & Amortization | $124K | $97K | $82K | -- | $81K | $76K | $79K | -- |
| Stock-Based Compensation | $3.67M | $4.90M | $2.57M | $2.34M | $881K | $335K | $634K | -- |
| **Operating Cash Flow** | -$64.29M | -$37.63M | -$23.29M | -$18.10M | -$3.37M | -$5.60M | -$8.13M | -- |
| Capital Expenditure | -$70K | -$363K | -$32K | -$40K | $0 | $9.0K | -$21K | -- |
| **Free Cash Flow** | -$64.36M | -$37.99M | -$23.32M | -$18.14M | -$3.37M | -$5.59M | -$8.15M | -- |
| **Investing Cash Flow** | -$144.7M | $89K | -$32K | -$40K | -$44.84M | $9.0K | $4.98M | -- |
| **Financing Cash Flow** | $140.9M | -$19K | $93.83M | -$1.17M | $303.7M | $0 | $0 | -- |
| **Net Change in Cash** | -$68.03M | -$37.56M | $70.51M | -$19.31M | $255.5M | -$5.59M | -$3.15M | -- |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 |
| --- | --- | --- |
| Return on Equity (ROE) | -8.4% | -- |
| Return on Assets (ROA) | -8.1% | -188.2% |
| Current Ratio | 41.44x | 3.56x |
| Quick Ratio | 39.67x | 3.14x |
| Debt to Equity | 0.01x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -33.8% | -25.8% | -10.3% | -8.4% | -6.1% | -- | -- | -- |
| Return on Assets (ROA) | -31.1% | -23.7% | -9.9% | -8.1% | -5.9% | -- | -- | -188.2% |
| Current Ratio | 14.78x | 15.08x | 35.68x | 41.44x | 47.60x | -- | -- | 3.56x |
| Quick Ratio | 13.33x | 13.79x | 33.45x | 39.67x | 47.31x | -- | -- | 3.14x |
| Debt to Equity | 0.01x | 0.02x | 0.01x | 0.01x | 0.01x | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
